Hello @madieblue , I'm thrilled to hear you're doing well on Keytruda. I personally stopped treatment after 14 rounds due to adverse effects, including high blood pressure, eye pain and blurriness, elevated glucose levels, prediabetes, obesity, inflammation, incontinence, skin rashes, bowel issues, and joint pain (early signs osteoporosis).

Although I showed no evidence of disease since surgery, and my CA 125 marker was within normal range after the first round of chemo, I felt my oncologist was dismissing my concerns about these symptoms. Seeking a second opinion revealed that there's no data supporting treatment beyond a year, except for lung or melanoma cases.

However, based on FDA and Keytruda.com guidelines, I understood that treatment can continue until disease progression, and the 24-month mark doesn't necessarily mean stopping at or extending beyond that point: 'The recommended pembrolizumab dose is 200 mg every 3 weeks or 400 mg every 6 weeks until disease progression, unacceptable toxicity, or up to 24 months.'

Please continue to fall, maintain the positivity you have, and advocate for yourself.

Stay well and best regards!